Day: January 25, 2019

Basilea Announces Collaboration to Study Derazantinib & Atezolizumab (Tecentriq®) in Urothelial Cancer

From Startup ARQULE Link to Full Article: BURLINGTON, Mass.–(BUSINESS WIRE)–Jan. 24, 2019– ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in